Biotech · Private company · San Diego, CA, US
Oncternal Therapeutics, Inc.
SEC CIK 0001260990
Track this companyFree. Adds Oncternal Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials61 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline10
- Bridging TherapyPhase 2 · Relapsed/Refractory Aggressive B-Cell MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- Cirmtuzumab (2-16 kg/mg) plus IbrutinibPhase 2 · B-cell Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Cirmtuzumab (300mg) plus IbrutinibPhase 2 · B-cell Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Cirmtuzumab (600 mg) plus ibrutinibPhase 2 · B-cell Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Cirmtuzumab (RDR) plus ibrutinibPhase 2 · B-cell Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Cirmtuzumab plus ibrutinibPhase 2 · B-cell Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Ibrutinib alonePhase 2 · B-cell Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- ONCT-534Phase 2 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- ONCT-808Phase 2 · Relapsed/Refractory Aggressive B-Cell MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- TK216Phase 2 · Sarcoma, EwingClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.PHASE1_PHASE2 · TERMINATED · started Sep 20, 2023ClinicalTrials.gov NCT05917470 · fetched Nov 12, 2026
- A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell MalignanciesPHASE1_PHASE2 · TERMINATED · started May 9, 2023ClinicalTrials.gov NCT05588440 · fetched Nov 12, 2026
- Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on VenetoclaxPHASE2 · ACTIVE_NOT_RECRUITING · started Aug 6, 2020ClinicalTrials.gov NCT04501939 · fetched Nov 12, 2026
- Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast CancerPHASE1 · COMPLETED · started Aug 15, 2018ClinicalTrials.gov NCT02776917 · fetched Nov 12, 2026
- A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid MalignanciesPHASE1_PHASE2 · COMPLETED · started Jan 3, 2018ClinicalTrials.gov NCT03088878 · fetched Nov 12, 2026
- TK216 in Patients With Relapsed or Refractory Ewing SarcomaPHASE1_PHASE2 · TERMINATED · started Aug 1, 2016ClinicalTrials.gov NCT02657005 · fetched Nov 12, 2026
SEC filings2
NIH awards2
- Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as New Potential Therapeutic for Kennedy's DiseaseFiscal year 2024 · $50KNIH RePORTER 3R44NS130806-02S1 · fetched Nov 12, 2026
- Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's DiseaseFiscal year 2024 · $1MNIH RePORTER 5R44NS130806-02 · fetched Nov 12, 2026